2020
Updates in staging and pathologic evaluation of esophageal carcinoma following neoadjuvant therapy
Zhang X, Jain D. Updates in staging and pathologic evaluation of esophageal carcinoma following neoadjuvant therapy. Annals Of The New York Academy Of Sciences 2020, 1482: 163-176. PMID: 32892349, DOI: 10.1111/nyas.14462.Peer-Reviewed Original ResearchConceptsNeoadjuvant therapyEsophageal cancerEsophageal carcinomaRecent American Joint CommitteePreoperative neoadjuvant therapyThorough pathologic assessmentTumor regression gradingAdvanced esophageal carcinomaAmerican Joint CommitteeCancer (AJCC) staging systemTumor regression gradeAccurate tumor stagingValuable prognostic informationRegression gradingSurgical resectionLymph nodesPathologic assessmentRegression gradeHistologic typePathologic evaluationResidual tumorPoor prognosisCell carcinomaGastrointestinal carcinomasStaging system
2019
Adverse Histologic Features in Colorectal Nonpedunculated Malignant Polyps With Nodal Metastasis
Patel N, Vyas M, Celli R, Jain D, Zhang X. Adverse Histologic Features in Colorectal Nonpedunculated Malignant Polyps With Nodal Metastasis. The American Journal Of Surgical Pathology 2019, 44: 241-246. PMID: 31498179, DOI: 10.1097/pas.0000000000001369.Peer-Reviewed Original ResearchConceptsHigh-grade tumor buddingAdverse histologic featuresMalignant polypsNodal metastasisTumor buddingHistologic featuresLymphovascular invasionNode metastasisLymph node metastatic potentialMargin statusSubsequent resectionColectomy specimenColectomy proceduresDifferentiated clustersTumor differentiationOdds ratioRisk featuresMetastasisMetastatic potentialPiecemeal polypectomyPolypsRiskInvasionColectomyResectionMacrotrabecular Hepatocellular Carcinoma
Jeon Y, Benedict M, Taddei T, Jain D, Zhang X. Macrotrabecular Hepatocellular Carcinoma. The American Journal Of Surgical Pathology 2019, 43: 943-948. PMID: 31135484, DOI: 10.1097/pas.0000000000001289.Peer-Reviewed Original ResearchMeSH KeywordsAgedAlpha-FetoproteinsCarcinoma, HepatocellularDisease ProgressionFemaleHepatectomyHepatitis BHepatitis CHumansLiver CirrhosisLiver NeoplasmsLiver TransplantationMaleMiddle AgedNeoplasm GradingNeoplasm Recurrence, LocalNeoplasm StagingProgression-Free SurvivalRetrospective StudiesRisk FactorsTime FactorsTumor BurdenConceptsHepatocellular carcinomaHCC subtypesHigh alpha-fetoprotein levelsWorse recurrence-free survivalDistinct HCC subtypeHepatitis C infectionRecurrence-free survivalAlpha-fetoprotein levelsAnaplastic tumor cellsHigh histologic gradePoor overall survivalConventional hepatocellular carcinomaHigh recurrence rateHigher AJCC stageDetailed pathologic evaluationMacrotrabecular patternC infectionPrimary resectionHepatitis BOverall survivalPathologic evaluationAJCC stageClinicopathologic featuresHistologic subtypeRecurrence rate
2016
HER2 Testing and Clinical Decision Making in Gastroesophageal Adenocarcinoma: Guideline From the College of American Pathologists, American Society for Clinical Pathology, and American Society of Clinical Oncology
Bartley AN, Washington MK, Ventura CB, Ismaila N, Colasacco C, Benson AB, Carrato A, Gulley ML, Jain D, Kakar S, Mackay HJ, Streutker C, Tang L, Troxell M, Ajani JA. HER2 Testing and Clinical Decision Making in Gastroesophageal Adenocarcinoma: Guideline From the College of American Pathologists, American Society for Clinical Pathology, and American Society of Clinical Oncology. Archives Of Pathology & Laboratory Medicine 2016, 140: 1345-1363. PMID: 27841667, DOI: 10.5858/arpa.2016-0331-cp.Peer-Reviewed Original ResearchMeSH KeywordsAdenocarcinomaBiomarkers, TumorClinical Decision-MakingCombined Modality TherapyDecision TreesDiagnosis, DifferentialEsophageal NeoplasmsEvidence-Based MedicineHumansMedical OncologyMolecular Diagnostic TechniquesMolecular Targeted TherapyMutationNeoplasm GradingNeoplasm StagingPathology, ClinicalReceptor, ErbB-2Societies, MedicalStomach NeoplasmsSystematic Reviews as TopicUnited StatesConceptsAdvanced gastroesophageal adenocarcinomaGastroesophageal adenocarcinomaEvidence-based guidelinesAssessment of HER2Clinical OncologyAmerican SocietyClinical decisionClinical pathologyAmerican PathologistsAccuracy of HER2Initial therapyMorphologic selectionOptimal HER2Combination chemotherapyHER2 statusOnly biomarkerSpecific therapyHER2 testingTumor specimensPatientsHER2Systematic reviewClinical implicationsNeoplastic tissueTherapy
2010
To Count and How to Count, That Is the Question
Parkash V, Bifulco C, Feinn R, Concato J, Jain D. To Count and How to Count, That Is the Question. American Journal Of Clinical Pathology 2010, 134: 42-49. PMID: 20551265, DOI: 10.1309/ajcpo92dzmucgeuf.Peer-Reviewed Original Research